Dermata Therapeutics (NASDAQ:DRMA) Announces Earnings Results, Misses Expectations By $0.19 EPS

Dermata Therapeutics (NASDAQ:DRMA) released its earnings results on Tuesday. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.19), FiscalAI reports.

Dermata Therapeutics Trading Up 22.7%

Shares of DRMA stock traded up $0.24 during mid-day trading on Wednesday, reaching $1.32. The stock had a trading volume of 13,296,638 shares, compared to its average volume of 1,111,748. The business’s fifty day moving average is $1.24 and its 200-day moving average is $1.36. The firm has a market cap of $5.33 million, a price-to-earnings ratio of -0.25 and a beta of 0.66. Dermata Therapeutics has a 1-year low of $0.95 and a 1-year high of $6.58.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Dermata Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.00.

Institutional Investors Weigh In On Dermata Therapeutics

An institutional investor recently bought a new stake in Dermata Therapeutics stock. Clear Street Group Inc. purchased a new position in Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned 0.60% of Dermata Therapeutics at the end of the most recent quarter. 8.67% of the stock is currently owned by institutional investors and hedge funds.

About Dermata Therapeutics

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.